Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (496) 496
Publication (72) 72
Book Chapter (12) 12
Magazine Article (11) 11
Book Review (6) 6
Conference Proceeding (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (325) 325
melarsoprol (304) 304
animals (287) 287
trypanosomiasis, african - drug therapy (249) 249
melarsoprol - therapeutic use (158) 158
trypanocidal agents - therapeutic use (138) 138
female (135) 135
human african trypanosomiasis (131) 131
male (127) 127
index medicus (122) 122
sleeping sickness (112) 112
tropical medicine (103) 103
trypanosomiasis (99) 99
parasitology (96) 96
trypanosoma brucei gambiense (91) 91
african trypanosomiasis (89) 89
mice (86) 86
adult (85) 85
trypanocidal agents - pharmacology (85) 85
melarsoprol - pharmacology (72) 72
trypanosomiasis, african - parasitology (72) 72
drug resistance (67) 67
trypanosomiasis, african - epidemiology (64) 64
eflornithine (62) 62
middle aged (62) 62
parasitic diseases (62) 62
public, environmental & occupational health (61) 61
trypanosoma brucei brucei - drug effects (61) 61
pharmacology & pharmacy (58) 58
trypanosomiasis, african - diagnosis (58) 58
adolescent (57) 57
infectious diseases (56) 56
eflornithine - therapeutic use (53) 53
pentamidine (53) 53
chemotherapy (50) 50
melarsoprol - administration & dosage (49) 49
melarsoprol - adverse effects (48) 48
risk-factors (48) 48
brucei-gambiense (45) 45
drug therapy, combination (45) 45
microbiology (44) 44
trypanocidal agents - administration & dosage (44) 44
child (42) 42
arsenicals - therapeutic use (41) 41
pentamidine - therapeutic use (41) 41
trypanosoma brucei rhodesiense (41) 41
gambiense sleeping sickness (40) 40
suramin - therapeutic use (40) 40
trypanosoma brucei gambiense - drug effects (40) 40
recurrence (39) 39
suramin (38) 38
treatment outcome (37) 37
drug therapy (36) 36
trypanosoma brucei (36) 36
uganda (36) 36
diagnosis (34) 34
gambiense (34) 34
in-vitro (34) 34
resistance (34) 34
trypanosoma brucei rhodesiense - drug effects (34) 34
child, preschool (31) 31
drug-resistance (30) 30
efficacy (30) 30
trypanocidal agents - adverse effects (30) 30
medicine, general & internal (29) 29
nifurtimox (29) 29
aged (28) 28
arsenicals - pharmacology (28) 28
research article (27) 27
treatment failure (27) 27
trial (27) 27
trypanosoma brucei brucei - metabolism (27) 27
trypanosomiasis, african - prevention & control (27) 27
biochemistry & molecular biology (26) 26
parasites (26) 26
pentamidine - pharmacology (26) 26
analysis (25) 25
drugs (25) 25
rats (25) 25
trypanosomiasis, african (25) 25
research (24) 24
african trypanosomes (23) 23
drug administration schedule (23) 23
encephalopathy (23) 23
immunology (23) 23
nifurtimox - therapeutic use (23) 23
trypanocidal agents - pharmacokinetics (23) 23
adenosine transporter (22) 22
blood-stream forms (22) 22
brucei (22) 22
follow-up studies (22) 22
time factors (22) 22
trypanocidal agents - chemistry (22) 22
trypanosoma brucei brucei (22) 22
cerebrospinal-fluid (21) 21
congo (21) 21
cross-resistance (21) 21
failure (21) 21
trypanosomiasis, african - cerebrospinal fluid (21) 21
arsenic (20) 20
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis
by Simarro, P.P and Franco, J and Diarra, A and Postigo, J.A.Ruiz and Jannin, J
Parasitology, ISSN 0031-1820, 06/2012, Volume 139, Issue 7, pp. 842 - 846
Despite the fact that eflornithine was considered as the safer drug to treat human African trypanosomiasis (HAT) and has been freely available since 2001, the... 
eflornithine | treatment combinations | nifurtimox | African trypanosomiasis | melarsoprol | TRIAL | RISK-FACTORS | COMBINATION THERAPY | GAMBIENSE SLEEPING SICKNESS | PARASITOLOGY | UGANDA | Trypanosomiasis, African - drug therapy | Humans | Melarsoprol - therapeutic use | Eflornithine - economics | Eflornithine - therapeutic use | Trypanocidal Agents - economics | Trypanosomiasis, African - parasitology | Animals | Health Services Accessibility | Nifurtimox - economics | Trypanocidal Agents - therapeutic use | Melarsoprol - economics | Drug Therapy, Combination | Nifurtimox - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Comparison of nanosuspensions and hydroxypropyl-β-cyclodextrin complex of melarsoprol: Pharmacokinetics and tissue distribution in mice
by Ben Zirar, Siham and Astier, Alain and Muchow, Marc and Gibaud, Stéphane
European Journal of Pharmaceutics and Biopharmaceutics, ISSN 0939-6411, 2008, Volume 70, Issue 2, pp. 649 - 656
The aim of this work was to develop and compare two formulations of melarsoprol (nanosuspension and hydroxypropyl-β-cyclodextrin inclusion complex). The... 
Melarsoprol | Cyclodextrin | Nanosuspensions | Arsenic | Leukemia | CELLS | TRYPANOCIDAL DRUG MELARSOPROL | BONE-MARROW | TRYPANOTHIONE | BLOOD-BRAIN-BARRIER | ARSTHINOL | HYDROCHLORIDE | NANOPARTICLES | IN-VITRO | PHARMACOLOGY & PHARMACY | ARSENICALS | 2-Hydroxypropyl-beta-cyclodextrin | Melarsoprol - pharmacology | Humans | Lethal Dose 50 | Trypanocidal Agents - pharmacokinetics | Chemistry, Pharmaceutical | Nanoparticles | Tissue Distribution | Animals | beta-Cyclodextrins - chemistry | Melarsoprol - pharmacokinetics | U937 Cells | K562 Cells | Melarsoprol - chemistry | Female | Antineoplastic Agents - pharmacology | Mice | Suspensions | Index Medicus | Antineoplastic Agents | Life Sciences | beta-Cyclodextrins | Trypanocidal Agents | Pharmaceutical sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Determination of the trypanocidal drug melarsoprol and its conversion products in biological fluids with HPLC–ICPMS/ESMS
by Raber, Thomas and Raber, Georg and Raml, Reingard and Murko, Manuela and Magnes, Christoph and Francesconi, Kevin A
Talanta, ISSN 0039-9140, 11/2013, Volume 116, pp. 876 - 881
Although melarsoprol, an organoarsenic compound, is widely used for the treatment of trypanosomiasis (human African sleeping sickness), very little is known... 
HPLC–ICPMS/ESMS | Melarsoprol | Sleeping sickness | Arsenic | HPLC-ICPMS/ESMS | Melarsoprol Sleeping sickness | CHEMISTRY, ANALYTICAL | HPLC ICPMS/ESMS | GAMBIENSE SLEEPING SICKNESS | BIOASSAY | Trypanocidal Agents - blood | Limit of Detection | Melarsoprol - pharmacology | Serum - metabolism | Drug Stability | Humans | Cells, Cultured | Blood Cells - metabolism | Trypanocidal Agents - chemistry | Blood Proteins - chemistry | Chromatography, High Pressure Liquid | Spectrophotometry, Atomic | Blood Cells - cytology | Spectrometry, Mass, Electrospray Ionization | Trypanocidal Agents - pharmacology | Biotransformation | Arsenicals - chemistry | Melarsoprol - chemistry | Protein Binding | Arsenic - blood | Arsenicals - blood | Blood Cells - drug effects | Melarsoprol - blood | Serum - chemistry | Proteins | Arson | Metabolites | Rain and rainfall | Protein binding
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis
by Rodgers, Jean and Jones, Amy and Gibaud, Stéphane and Bradley, Barbara and McCabe, Christopher and Barrett, Michael P and Gettinby, George and Kennedy, Peter G. E
PLoS Neglected Tropical Diseases, ISSN 1935-2727, 09/2011, Volume 5, Issue 9, p. e1308
Human African trypanosomiasis (HAT), or sleeping sickness, results from infection with the protozoan parasites Trypanosoma brucei (T.b.) gambiense or T.b.... 
ISSUES | RISK-FACTORS | BRUCEI-GAMBIENSE | PHARMACEUTICAL APPLICATIONS | BETA-CYCLODEXTRIN | SLEEPING SICKNESS | CENTRAL-NERVOUS-SYSTEM | BIOAVAILABILITY | BRAIN | CHEMOTHERAPY | PARASITOLOGY | TROPICAL MEDICINE | Trypanosomiasis, African - drug therapy | Brain - diagnostic imaging | Parasitic Sensitivity Tests | Humans | Melarsoprol - administration & dosage | Male | Cyclodextrins - chemistry | Blood-Brain Barrier - physiology | Melarsoprol - chemistry | Molecular Structure | Brain - parasitology | Disease Models, Animal | Melarsoprol - pharmacology | Administration, Oral | Parasite Load | Africa South of the Sahara | Models, Molecular | Treatment Outcome | Antiprotozoal Agents - chemistry | Antiprotozoal Agents - pharmacology | Trypanosoma brucei brucei - drug effects | Radiography | Magnetic Resonance Imaging | Animals | Cyclodextrins - administration & dosage | Antiprotozoal Agents - administration & dosage | Brain - pathology | Mice | Cyclodextrins - pharmacology | Chemotherapy | Care and treatment | Cyclodextrins | Research | Health aspects | Trypanosomiasis | Cancer | Brain | Melarsoprol | Trypanosomiasis, African | Trypanosoma brucei brucei | Life Sciences | Antiprotozoal Agents | Medication | Pharmaceutical sciences | Blood-Brain Barrier
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Chemotherapy of Human African Trypanosomiasis
by Burchmore, RJS and Ogbunude, POJ and Enanga, B and Barrett, MP
Current Pharmaceutical Design, ISSN 1381-6128, 01/2002, Volume 8, Issue 4, pp. 257 - 267
Human African trypanosomiasis or sleeping sickness is resurgent. The disease is caused by subspecies of the parasitic haemoflagellate, Trypanosoma brucei.... 
melarsoprol
Journal Article
Details down arrow
6. Full Text Chemotherapy for second-stage human African trypanosomiasis
by Lutje, Vittoria and Lutje, Vittoria and Seixas, Jorge and Seixas, Jorge and Kennedy, Adrian and Kennedy, Adrian
The Cochrane database of systematic reviews, ISSN 1469-493X, 2013, Volume 6, Issue 6, p. CD006201
Background Human African trypanosomiasis, or sleeping sickness, is a painful and protracted disease affecting people in the poorest parts of Africa and is... 
Antiprotozoal Agents [adverse effects; therapeutic use] | Recurrence | 10-DAY MELARSOPROL SCHEDULE | DRUG-COMBINATIONS | MULTICENTER | Melarsoprol [therapeutic use] | Humans | Nifurtimox [therapeutic use] | RANDOMIZED CLINICAL-TRIAL | GAMBIAN TRYPANOSOMIASIS | Trypanosomiasis, African [drug therapy] | EFLORNITHINE COMBINATION THERAPY | Trypanosoma brucei gambiense | REGIMENS | NIFURTIMOX | Randomized Controlled Trials as Topic | MEDICINE, GENERAL & INTERNAL | Drug Therapy, Combination [methods] | Animals | BRUCEI-GAMBIENSE | Prednisolone [therapeutic use] | Eflornithine [therapeutic use] | GAMBIENSE SLEEPING SICKNESS | Pentamidine [therapeutic use] | Trypanosomiasis, African - drug therapy | Pentamidine - therapeutic use | Melarsoprol - therapeutic use | Eflornithine - therapeutic use | Drug Therapy, Combination - methods | Antiprotozoal Agents - adverse effects | Prednisolone - therapeutic use | Antiprotozoal Agents - therapeutic use | Nifurtimox - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Treatment of human African trypanosomiasis—present situation and needs for research and development
by Legros, Dominique and Ollivier, Gaëlle and Gastellu-Etchegorry, Marc and Paquet, Christophe and Burri, Christian and Jannin, Jean and Büscher, Philippe
The Lancet Infectious Diseases, ISSN 1473-3099, 2002, Volume 2, Issue 7, pp. 437 - 440
Human African trypanosomiasis re-emerged in the 1980s. However, little progress has been made in the treatment of this disease over the past decades. The... 
INFECTIOUS DISEASES | MELARSOPROL | SURAMIN | EFLORNITHINE | EFFICACY | BRUCEI-GAMBIENSE | RHODESIENSE | GAMBIENSE SLEEPING SICKNESS | METRONIDAZOLE | COMBINATION | NIFURTIMOX | Trypanosomiasis, African - drug therapy | Trypanocidal Agents - adverse effects | Nifurtimox - administration & dosage | Humans | Trypanosoma brucei rhodesiense | Africa South of the Sahara | Melarsoprol - administration & dosage | Eflornithine - adverse effects | Melarsoprol - therapeutic use | Eflornithine - therapeutic use | Trypanosoma brucei gambiense | Melarsoprol - adverse effects | Animals | Nifurtimox - adverse effects | Thiadiazoles - therapeutic use | Benzamidines - therapeutic use | Trypanocidal Agents - therapeutic use | Drug Therapy, Combination | Eflornithine - administration & dosage | Nifurtimox - therapeutic use | Trypanocidal Agents - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Human African trypanosomiasis
by Brun, Reto, Prof and Blum, Johannes, MD and Chappuis, Francois, MD and Burri, Christian, PhD
Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9709, pp. 148 - 159
Summary Human African trypanosomiasis (sleeping sickness) occurs in sub-Saharan Africa. It is caused by the protozoan parasite Trypanosoma brucei , transmitted... 
Internal Medicine | NERVOUS-SYSTEM INVOLVEMENT | MEDICINE, GENERAL & INTERNAL | OF-THE-CONGO | POLYMERASE-CHAIN-REACTION | COTE-DIVOIRE | LATE-STAGE | INTRATHECAL IMMUNE-RESPONSE | CATT/TRYPANOSOMA-BRUCEI-GAMBIENSE | GAMBIENSE SLEEPING SICKNESS | CARD-AGGLUTINATION-TEST | CEREBROSPINAL-FLUID | Africa - epidemiology | Insect Vectors | Tsetse Flies - parasitology | Humans | Pentamidine - therapeutic use | Trypanosoma brucei gambiense - pathogenicity | Trypanosoma brucei gambiense - immunology | Melarsoprol - therapeutic use | Insect Bites and Stings - prevention & control | Eflornithine - therapeutic use | Communicable Disease Control - methods | Incidence | Variant Surface Glycoproteins, Trypanosoma - immunology | Trypanosomiasis, African - transmission | Animals | Trypanosomiasis, African - diagnosis | Suramin - therapeutic use | Trypanosomiasis, African - epidemiology | Biomedical Research | Trypanocidal Agents - therapeutic use | Endemic Diseases - prevention & control | Trypanosomiasis, African - therapy | Drugs | Insects | Medical diagnosis | Rural areas | Health services | Tropical diseases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Melarsoprol–cyclodextrins inclusion complexes
by Gibaud, Stéphane and Zirar, Siham Ben and Mutzenhardt, Pierre and Fries, Isabelle and Astier, Alain
International Journal of Pharmaceutics, ISSN 0378-5173, 2005, Volume 306, Issue 1, pp. 107 - 121
Melarsoprol, a water-insoluble drug, is mainly used in the treatment of trypanosomiasis and has demonstrated an in vitro activity on myeloid and lymphoid... 
Melarsoprol | Complexation | Cytotoxicity | Hydroxypropyl-β-cyclodextrin | Nuclear magnetic resonance | Methylated-β-cyclodextrin | Hydroxypropyl-β- cyclodextrin | hydroxypropyl-beta-cyclodextrin | SOLUBILIZATION | TRYPANOCIDAL DRUG MELARSOPROL | PERFORMANCE | NUCLEAR-MAGNETIC-RESONANCE | METHYL-BETA | nuclear magnetic resonance | methylated-beta-cyclodextrin | AQUEOUS-SOLUTION | SPECTROSCOPY | BETA-CYCLODEXTRIN | PHARMACOLOGY & PHARMACY | complexation | ASSOCIATION | EFFICIENCY | cytotoxicity | melarsoprol | Cell Survival - drug effects | Magnetic Resonance Spectroscopy | Melarsoprol - pharmacology | Drug Stability | Humans | Solubility | Antineoplastic Agents - chemistry | Cyclodextrins - chemistry | Cell Line, Tumor | Drug Compounding | Melarsoprol - chemistry | Antineoplastic Agents - pharmacology | Molecular Structure | Kinetics | Cyclodextrins - pharmacology | Hydrolysis | Antiparasitic agents | Cyclodextrins | Analysis | Leukemia | Cell Survival | Antineoplastic Agents | Life Sciences | Pharmaceutical sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text The phenomenon of treatment failures in Human African Trypanosomiasis
by Brun, Reto and Schumacher, Reto and Schmid, Cecile and Kunz, Christina and Burri, Christian
Tropical Medicine & International Health, ISSN 1360-2276, 11/2001, Volume 6, Issue 11, pp. 906 - 914
Treatment of Human African Trypanosomiasis (HAT or sleeping sickness) relies on a few drugs which are old, toxic and expensive. The most important drug for the... 
treatment | drug resistance | relapse | Trypanosoma brucei gambiense | Trypanosoma brucei rhodesiense | melarsoprol | Melarsoprol | Relapse | Treatment | Drug resistance | RISK-FACTORS | T-GAMBIENSE | TRANSPORTER | SUSCEPTIBILITY | BRUCEI-RHODESIENSE | TROPICAL MEDICINE | IN-VITRO | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | INVITRO DRUG SENSITIVITY | RESISTANCE | GAMBIENSE TRYPANOSOMIASIS | Recurrence | Trypanocidal Agents - blood | Trypanosomiasis, African - drug therapy | Parasitic Sensitivity Tests | Humans | Melarsoprol - therapeutic use | Dose-Response Relationship, Drug | Trypanosoma brucei gambiense - drug effects | Treatment Failure | Trypanosomiasis, African - epidemiology | Trypanocidal Agents - cerebrospinal fluid | Trypanocidal Agents - therapeutic use | Trypanosoma brucei gambiense - isolation & purification | Africa, Eastern - epidemiology | Drug Resistance | Melarsoprol - cerebrospinal fluid | Trypanosoma brucei rhodesiense - isolation & purification | Trypanocidal Agents - pharmacokinetics | Trypanosomiasis, African - parasitology | Animals | Melarsoprol - pharmacokinetics | Muridae | Mice | Trypanosoma brucei rhodesiense - drug effects | Melarsoprol - blood
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Equivalence Trial of Melarsoprol and Nifurtimox Monotherapy and Combination Therapy for the Treatment of Second-Stage Trypanosoma brucei gambiense Sleeping Sickness
by Sylvie Bisser and François-Xavier N'Siesi and Veerle Lejon and Pierre-Marie Preux and Simon Van Nieuwenhove and Constantin Miaka Mia Bilenge and Philippe Büscher
The Journal of Infectious Diseases, ISSN 0022-1899, 2/2007, Volume 195, Issue 3, pp. 322 - 329
Background. Treatment of second-stage sleeping sickness relies mainly on melarsoprol. Nifurtimox has been successfully used to cure melarsoprol-refractory... 
Relapse | Health care administration | Encephalopathies | Cerebrospinal fluid | Parasites | Dosage | Patient assessment | Trypanosomiasis | African trypanosomiasis | Blood | Trypanosome | INFECTIOUS DISEASES | RISK-FACTORS | CLINICAL-TRIAL | EFFICACY | HUMAN AFRICAN TRYPANOSOMIASIS | T-B.-GAMBIENSE | SITUATION | MICROBIOLOGY | IMMUNOLOGY | FUTURE-PROSPECTS | CHEMOTHERAPY | LATE-STAGE | SCHEDULE | Recurrence | Trypanosomiasis, African - drug therapy | Injections, Intravenous | Drug Administration Schedule | Administration, Oral | Humans | Melarsoprol - administration & dosage | Male | Melarsoprol - therapeutic use | Treatment Outcome | Trypanosoma brucei gambiense | Brain Diseases - chemically induced | Melarsoprol - adverse effects | Animals | Adult | Female | Trypanocidal Agents - therapeutic use | Drug Therapy, Combination | Nifurtimox - therapeutic use | Sleep disorders | Care and treatment | Patient outcomes | Causes of | Research | Trypanosoma brucei | Drug therapy | Parasitology | Nifurtimox | Melarsoprol | Trypanosomiasis, African | Life Sciences | Microbiology and Parasitology | Trypanocidal Agents | Brain Diseases | Santé publique et épidémiologie
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text A sensitive and reproducible in vivo imaging mouse model for evaluation of drugs against late-stage human African trypanosomiasis
by Burrell-saward, Hollie and Rodgers, Jean and Bradley, Barbara and Croft, Simon L and Ward, Theresa H
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 02/2015, Volume 70, Issue 2, pp. 510 - 517
Objectives: To optimize the Trypanosoma brucei brucei GVR35 VSL-2 bioluminescent strain as an innovative drug evaluation model for late-stage human African... 
Trypanosoma brucei brucei | Luciferase | Bioluminescence imaging | INFECTIOUS DISEASES | MELARSOPROL | EFFICACY | bioluminescence imaging | luciferase | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | MICE | BRUCEI-BRUCEI | Reproducibility of Results | Melarsoprol - pharmacology | Humans | Parasite Load | Melarsoprol - administration & dosage | Luminescent Measurements - methods | Trypanosoma brucei brucei - drug effects | Diagnostic Imaging - methods | Dose-Response Relationship, Drug | Trypanosomiasis, African - parasitology | Animals | Trypanosomiasis, African - diagnosis | Trypanocidal Agents - pharmacology | Sensitivity and Specificity | Female | Mice | Disease Models, Animal | Trypanocidal Agents - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text In vitro and in vivo evaluation of 28DAP010, a novel diamidine for treatment of second-stage African sleeping sickness
by Wenzler, Tanja and Yang, Sihyung and Patrick, Donald A and Braissant, Olivier and Ismail, Mohamed A and Tidwell, Richard R and Boykin, David W and Wang, Michael Zhuo and Bruna, Reto
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 2014, Volume 58, Issue 8, pp. 4452 - 4463
African sleeping sickness is a neglected tropical disease transmitted by tsetse flies. New and better drugs are still needed especially for its second stage,... 
AZA-ANALOGS | PENTAMIDINE | TRYPANOSOMA-BRUCEI-GAMBIENSE | PRODRUG DB289 | MELARSOPROL | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | ANTIPROTOZOAL ACTIVITY | DRUG-RESISTANCE | BINDING | CYP4F ENZYMES | ISOTHERMAL MICROCALORIMETRY | Trypanosomiasis, African - drug therapy | Humans | Pyridines - pharmacokinetics | Structure-Activity Relationship | Dose-Response Relationship, Drug | Pentamidine - pharmacokinetics | Trypanosoma brucei gambiense - drug effects | Amidines - pharmacokinetics | Trypanosoma brucei rhodesiense - growth & development | Female | Amidines - chemical synthesis | Pentamidine - pharmacology | Melarsoprol - pharmacology | Trypanosoma brucei gambiense - growth & development | Trypanosoma brucei gambiense - pathogenicity | Pyridines - chemical synthesis | Trypanocidal Agents - pharmacokinetics | Trypanosomiasis, African - parasitology | Animals | Melarsoprol - pharmacokinetics | Trypanocidal Agents - pharmacology | Trypanosoma brucei rhodesiense - pathogenicity | Trypanocidal Agents - chemical synthesis | Amidines - pharmacology | Mice | Pyridines - pharmacology | Trypanosoma brucei rhodesiense - drug effects | Susceptibility
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text The antitumor effects of an arsthinol–cyclodextrin complex in a heterotopic mouse model of glioma
by Becherirat, Selma and Lanhers, Marie-Claire and Socha, Marie and Yemloul, Mehdi and Astier, Alain and Loboda, Caroline and Aniceto, Natália and Gibaud, Stéphane
European Journal of Pharmaceutics and Biopharmaceutics, ISSN 0939-6411, 11/2013, Volume 85, Issue 3, pp. 560 - 568
In this paper, we examined arsthinol–cyclodextrin complexes, which display an anticancer activity. The association constants were 17,502 ± 522 M for... 
Cyclodextrin | Glioma | Arsenic | Brain tumors | Glioblastoma | Cancer | INCLUSION COMPLEXES | AUTOPHAGIC CELL-DEATH | ARSENIC TRIOXIDE | MELARSOPROL | PHARMACOKINETICS | ANTILEUKEMIC ACTIVITY | BETA-CYCLODEXTRIN | BINDING CONSTANTS | PHARMACOLOGY & PHARMACY | POTENTIOMETRIC TITRATION | 2-Hydroxypropyl-beta-cyclodextrin | Humans | Oxides - chemistry | Brain Neoplasms - pathology | Melarsoprol - administration & dosage | Antineoplastic Agents - administration & dosage | Excipients - chemistry | Glioma - pathology | Melarsoprol - chemistry | Female | Antineoplastic Agents - pharmacology | Oxides - administration & dosage | Magnetic Resonance Spectroscopy | Melarsoprol - pharmacology | Arsenicals - pharmacology | Injections, Intraperitoneal | Antineoplastic Agents - chemistry | Brain Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Oxides - pharmacology | Arsenicals - administration & dosage | Animals | beta-Cyclodextrins - chemistry | Mice, Nude | Arsenicals - chemistry | Cell Line, Tumor | Mice | Glioma - drug therapy | Gliomas | Analysis | Cyclodextrins | Life Sciences | Pharmaceutical sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo
by Kazumba, Léon Mbiyangandu and Kaka, Jean-Claude Tshinzobe and Ngoyi, Dieudonné Mumba and Tshala-Katumbay, Désiré
PLoS Neglected Tropical Diseases, ISSN 1935-2727, 06/2018, Volume 12, Issue 6, p. e0006504
We conducted a retrospective study on mortality trends and risk factors in 781 naive cases of advanced stage-2 sleeping sickness admitted between 1989 and 2012... 
MULTICENTER | PROTEIN | BRUCEI-GAMBIENSE | GAMBIAN TRYPANOSOMIASIS | EFLORNITHINE COMBINATION THERAPY | SCHEDULE | CEREBROSPINAL-FLUID | PARASITOLOGY | TROPICAL MEDICINE | MELARSOPROL TREATMENT | Multivariate Analysis | Recurrence | Trypanosomiasis, African - drug therapy | Nifurtimox - administration & dosage | Humans | Middle Aged | Melarsoprol - administration & dosage | Male | Melarsoprol - therapeutic use | Eflornithine - therapeutic use | Young Adult | Trypanosoma brucei gambiense - drug effects | Trypanosomiasis, African - epidemiology | Trypanosomiasis, African - mortality | Adult | Female | Trypanocidal Agents - therapeutic use | Retrospective Studies | Drug Therapy, Combination | Eflornithine - administration & dosage | Trypanocidal Agents - administration & dosage | Risk Factors | Treatment Outcome | Hospital Records | Trypanosomiasis, African - parasitology | Democratic Republic of the Congo - epidemiology | Adolescent | Disease Management | Nifurtimox - therapeutic use | Mortality | Analysis | Africa | Congo (Kinshasa) | Epidemiology | Trypanosomiasis | Health aspects | Risk factors | Intravenous administration | Nifurtimox | Medical services | Parasites | Cerebrospinal fluid | Gender | Risks | Proteins | Regression models | Fluids | Ratios | Mathematical models | Trends | African trypanosomiasis | Vector-borne diseases | Evaluation | Computational fluid dynamics | Fluid | Duration | Regression analysis | Risk analysis | Patients | Body fluids | Neurology | Death | Eflornithine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights